Search

Your search keyword '"K. Fizazi"' showing total 206 results

Search Constraints

Start Over You searched for: Author "K. Fizazi" Remove constraint Author: "K. Fizazi" Search Limiters Full Text Remove constraint Search Limiters: Full Text
206 results on '"K. Fizazi"'

Search Results

1. Efficacy and safety of darolutamide (DARO) in patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and a prostate-specific antigen doubling time (PSADT) >6 months

5. 1421P Effect of abiraterone-prednisone in metastatic castration-sensitive prostate cancer (mCSPC) with neuroendocrine and very high-risk features in the PEACE-1 trial

9. Risk of residual teratoma after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumor and IGCCCG intermediate/poor prognosis: A multi-institutional retrospective cohort study

10. 1380P High Sonic Hedgehog (HH) signalling activity, low androgen receptor activity and clonal evolution are associated with resistance to androgen-receptor axis inhibitors in patients with metastatic prostate cancer

13. 1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit

15. 1742P Phase II study of rucaparib and atezolizumab (ARIANES): Results in patients (pts) with platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer (mCRPC)

17. Health-Related Quality of Life (HRQoL) in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

18. Patient-reported pain by baseline pain status in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

19. Patient-reported pain by clinical outcome in men with metastatic Castration-Resistant Prostate Cancer (mCRPC) receiving Talazoparib (TALA): TALAPRO-1

20. TALAPRO-3: A phase 3, double-blind, randomized study of enzalutamide (ENZA) plus talazoparib (TALA) vs placebo plus ENZA in patients (pts) with DDR gene mutated metastatic castration-sensitive prostate cancer (mCSPC)

21. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer

22. Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castrationresistant prostate cancer: a report from the PETRUS prospective study

23. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis

24. Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients

25. Additional file 1: Figure S1. of Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer

26. Post hoc responder analysis of health‐related quality of life (HRQL) in patients with metastatic castration‐resistant prostate cancer (mCRPC) receiving cabazitaxel in the phase III PROSELICA and FIRSTANA trials

27. Testicular seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

29. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

31. Prostate cancer: ESMO Consensus Conference Guidelines 2012

32. Etude prospective de la symptomatologie clinique précoce après irradiation corporelle totale thérapeutique de 2 Gy

34. 2-¹⁸fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial

35. Oxaliplatin in non-seminomatous germ-cell tumors

36. A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trial

37. PCN128 EQ-5D Utility Index in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) With Progression During or After First-Line Docetaxel Therapy

38. Prostate cancer cells induce osteoblast differentiation through a Cbfa1-dependent pathway

42. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity.

43. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study.

46. A phase II multicenter study of oxaliplatin in combination with paclitaxel in poor prognosis patients who failed cisplatin-based chemotherapy for germ-cell tumors.

47. The postchemotherapy PSA surge syndrome.

48. Refining the optimal chemotherapy regimen for good-risk metastatic nonseminomatous germ-cell tumors: a randomized trial of the Genito-Urinary Group of the French Federation of Cancer Centers (GETUG T93BP).

49. Darolutamide in Japanese patients with metastatic hormone-sensitive prostate cancer: Phase 3 ARASENS subgroup analysis.

50. Multivariable models of outcomes with [ 177 Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.

Catalog

Books, media, physical & digital resources